Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We are pleased to announce that Prof Joel Tarning has been awarded the biennial Grahame-Smith Prize by the British Pharmacological Society for outstanding contributions to clinical pharmacology. Joel has headed MORU's Clinical Pharmacology Department since 2012. Since then, the Department has grown into large, productive group that conducts laboratory- and computer-based pharmacology research.

Profesor Joel Tarning in a laboratory. © 2020 MORU. Photographer: Gerhard Jørén

Prof David Grahame-Smith, after whom the award Joel was honoured with is named, was Professor of Pharmacology at Oxford for several decades,” said Prof Nick Day, MORU Director. “He taught me as a medical student, and both Nick White and I both worked for him as junior doctors. He was a wonderful man, very funny and deeply humane in his clinical practice. It is very fitting that Joel has won an award associated with such a giant in the field.”

Joel's research interests include infectious disease pharmacology and the use of novel pharmacometric methodologies to identify and optimise the dose in particularly vulnerable populations, such as children and pregnant women. His work on the pharmacokinetic and pharmacodynamic properties of antimalarial drugs in young children with uncomplicated and severe malaria has already had a global impact, resulting in revised WHO Guidelines for the treatment of malaria. 

"David Grahame-Smith was a wonderful man," said Prof Sir Nick White. "Nick Day and I both worked for him. He was cheerful, positive, amusing and down to earth as well as being a world leading clinical pharmacologist and a very good physician. He was also an excellent jazz pianist. It is really nice for Joel to have deservedly won this award and, in doing so, to revive his memory."

As part of his award, Joel has been invited to give a prize lecture at a future, physical meeting of the Society. Please join us in extending your congratulations to Joel.

- Text by John Bleho

Similar stories

Congratulations Professor Sir David Warrell, appointed Knight Commander of the Order of St Michael and St George

David Warrell, our founding director, has been appointed by the Queen ‘Knight Commander of the Order of St Michael and St George for services to global Health Research and Clinical Practice’. Please join us in congratulating Sir David on receiving this richly deserved high honour!

Patient recruitment on track in Oxford-led DeTACT trial of safe, effective drug combinations to prevent the spread of artemisinin and multi-drug resistant malaria in Africa

Today is World Malaria Day. The global fight against malaria is at a critical point. No new antimalarial drugs are expected in the near future, and if multi-drug resistant falciparum malaria becomes established in East Africa and spreads to other parts of Africa, millions will be at risk of drug-resistant malaria infection and death. The development of triple artemisinin-based combination therapies aims to prevent or delay the emergence of artemisinin and multi-drug resistant malaria in Africa.

TACT-CV study shows artemether–lumefantrine plus amodiaquine an effective treatment for multidrug-resistant malaria in GMS

A triple artemisinin-based combination therapy (TACT) of artemether-lumefantrine plus amodiaquine (AL+AQ) for uncomplicated falciparum malaria in areas with a high prevalence of artemisinin resistance is a well-tolerated, effective treatment for multidrug-resistant parasites, say a team of MORU-led researchers.

Largest-ever IPD meta-analysis of malaria patients to inform haemoglobin changes

A new malaria study using a very large analysis of pooled individual patient data (IPD) from more than 70,000 patients of all ages, has been published in BMC Medicine by the WorldWide Antimalarial Resistance Network Falciparum Haematology Study Group

Study finds steady increase in WHO-validated artemisinin resistance markers in Asia

From 2002-2018, there has been a steady increase in the places and proportion of infected people reporting validated kelch13 (K13) artemisinin resistance markers, according to a study in The Lancet Microbe. This increase in artemisinin resistance threatens efforts to eliminate malaria in Asia by 2030 — and control efforts in other endemic regions. The authors say that more consistent data collection, over longer time periods in the same areas, and rapid sharing of data are needed to map the spread of resistance and better inform policy decisions.

Global Research on AntiMicrobial resistance (GRAM) project

Antimicrobial resistance (AMR) is responsible for at least 1.27 million deaths per year — with over 97,000 deaths in 2019 in SE Asia alone, according to a study published in The Lancet by the Global Research on AntiMicrobial resistance (GRAM) project, who urged urgent action from policymakers and health communities to avoid further preventable deaths.